Evolus (NASDAQ:EOLS) Now Covered by Analysts at Needham & Company LLC


Research analysts at Needham & Company LLC coverage on shares of Evolus (NASDAQ:EOLS – Get Rating) in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage set a “buy” rating on the stock.

Other equities research analysts have also recently issued research reports about the company. Barclays upgraded Evolus from an “underweight” rating to an “equal weight” rating and boosted their objective price for the company from $8.00 to $10.00 in a research note on Thursday, May 12th. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Evolus in a research report on Friday, March 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of Evolus in a research report on Friday, March 4th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.80.

NASDAQ:EOLS opened at $11.51 on Thursday. The firm has a market cap of $645.14 million, a PE ratio of -8.85 and a beta of 2.07. The company has a 50-day moving average of $11.84 and a 200 day moving average of $9.54. Evolus has a 1-year low of $5.06 and a 1-year high of $14.34. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.51 and a quick ratio of 3.42.

(Ad)

What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

Evolus (NASDAQ:EOLS – Get Rating) last announced its earnings results on Tuesday, May 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.24. Evolus had a negative return on equity of 80.20% and a negative net margin of 58.28%. The firm had revenue of $33.90 million for the quarter, compared to analyst estimates of $29.83 million. During the same quarter last year, the firm posted $0.16 EPS. The business’s revenue was up 177.9% on a year-over-year basis. Sell-side analysts anticipate that Evolus will post -1.07 EPS for the current fiscal year.

In other news, insider David Moatazedi sold 6,104 shares of the firm’s stock in a transaction on Monday, March 28th. The stock was sold at an average price of $11.62, for a total value of $70,928.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Lauren P. Silvernail sold 52,015 shares of the firm’s stock in a transaction on Wednesday, May 18th. The stock was sold at an average price of $12.42, for a total value of $646,026.30. Following the completion of the sale, the insider now directly owns 141,571 shares of the company’s stock, valued at approximately $1,758,311.82. The disclosure for this sale can be found here. Insiders sold a total of 123,753 shares of company stock worth $1,609,234 over the last 90 days. Insiders own 7.60% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Hong Kong Ltd boosted its position in Evolus by 979.7% during the first quarter. Point72 Hong Kong Ltd now owns 2,343 shares of the company’s stock valued at $26,000 after purchasing an additional 2,126 during the last quarter. Metropolitan Life Insurance Co NY acquired a new stake in Evolus during the first quarter valued at $26,000. Citigroup Inc. boosted its position in Evolus by 230.9% during the third quarter. Citigroup Inc. Now owns 5,090 shares of the company’s stock shares valued at $39,000 after purchasing an additional 3,552 during the last quarter. Nisa Investment Advisors LLC boosted its position in Evolus by 945.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,750 shares of the company’s stock valued at $43,000 after purchasing an additional 5,200 shares during the last quarter. Finally, Zurcher Cantonalbank Zurich Cantonalbank acquired a new stake in Evolus during the first quarter valued at $60,000. 36.94% of the stock is owned by hedge funds and other institutional investors.

Evolus Company Profile (Get Rating)

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Articles

The Fly logo

Analyst Recommendations for Evolus (NASDAQ:EOLS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email┬áprotected]

Should you invest $1,000 in Evolus right now?

Before you consider Evolus, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Evolus wasn’t on the list.

While Evolus currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

.

Leave a Comment